Dabigatran

• 

  Subject Areas on Research

  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). 
  • A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. 
  • Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 
  • Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. 
  • Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. 
  • Anticoagulation in atrial fibrillation. 
  • Anticoagulation, novel agents, and procedures: can we pardon the interruption? 
  • Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. 
  • Balancing Bleeding and Clotting: The Known Unknowns of Mechanically Assisted Circulation. 
  • Bleeding and the new anticoagulants: strategies and concerns. 
  • Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? 
  • Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. 
  • Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. 
  • Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. 
  • DVT: a new era in anticoagulant therapy. 
  • Dabigatran Compared With Rivaroxaban vs Warfarin. 
  • Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. 
  • Dabigatran abrogates brain endothelial cell permeability in response to thrombin. 
  • Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. 
  • Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. 
  • Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. 
  • Dabigatran versus warfarin in patients with mechanical heart valves. 
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. 
  • Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? 
  • Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 
  • Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). 
  • Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. 
  • Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. 
  • Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. 
  • Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. 
  • Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 
  • Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. 
  • Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. 
  • Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. 
  • Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. 
  • How country-specific should a country-specific cost-effectiveness analysis be? 
  • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 
  • Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. 
  • Idarucizumab for Dabigatran Reversal. 
  • Idarucizumab for dabigatran overdose. 
  • Intracerebral hemorrhage and thrombin-induced alterations in cerebral microvessel matrix. 
  • Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. 
  • Letter to the Editor: Managing Dabigatran-Related Bleeding. 
  • Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. 
  • Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis. 
  • Managing new oral anticoagulants in the perioperative and intensive care unit setting. 
  • Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. 
  • Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. 
  • Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. 
  • Novel oral anticoagulants in gastroenterology practice. 
  • Perioperative coagulation management: Evolving strategies. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists. 
  • Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. 
  • Positive outcome after intentional overdose of dabigatran. 
  • Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. 
  • Precision Correction of Coagulopathy or Prothrombin Complex Concentrates?: Reversal Options for Dabigatran following Trauma. 
  • Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. 
  • Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. 
  • Promise of factor Xa inhibition in atrial fibrillation. 
  • Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. 
  • Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials. 
  • Role of coagulation factor concentrates for reversing dabigatran-related anticoagulation. 
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 
  • Stroke prevention in atrial fibrillation: Closing the gap. 
  • The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? 
  • The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. 
  • Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. 
  • Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II.